VIENNA — Twelve-month data from the Personalised Anti-TNF Therapy in Crohn’s Disease trial, known as PANTS, are among the highly anticipated research findings to be presented at the upcoming European Crohn’s and Colitis Organisation (ECCO) 2018 Congress.
“I think that it will be an exciting presentation,” said James Lindsay, PhD, BM BCh, education officer and a member of the governing board of ECCO. “It’s a prospective cohort study looking for pharmacogenetic predictors of response and the development of antidrug antibody formation with anti-TNF agents. And it’s got a great acronym: PANTS.”
Dr James Lindsay
Barts and the London School of Medicine and Dentistry
The investigator-led “real life” study assesses 1601 participants for primary nonresponse, loss of response, and antidrug antibody formation after treatment with one of three anti-TNF agents: infliximab, the biosimilar CT-P13, and adalimumab.
PANTS will be followed by the UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease — or VEST — trial, which is scheduled to be completed by the end of 2019 (NCT03257345), Dr Lindsay reported.
“The whole concept of predicting who will respond to a particular therapy, so you can target treatment appropriately, is really the Holy Grail of IBD management in the field of biologic agents,” he explained.
Studies that look at predicting treatment response in pediatric patients will also be presented at the meeting.
And, as a follow-up to the CELEST phase 2 trial, researchers plan to reveal the rapidity of onset of the JAK1 inhibitor upadacitinib. The team looked at clinical and objective markers of improvement in 220 people with active Crohn’s disease who are refractory to treatment with an immunomodulator or an anti-TNF agent.
Unanswered Questions
More anticipated results will come from another follow-up study: the VERSIFY trial. The original GEMINI-2 and -3 trials looked at vedolizumab in patients with Crohn’s disease but did not report on mucosal healing as a prospectively collected outcome. The VERSIFY trial was designed to determine whether “vedolizumab heals the mucosa in Crohn’s disease and, if it does, how long it takes to do it,” Dr Lindsay said.
Another hot topic in inflammatory bowel disease to be addressed is autologous hematopoietic stem cell transplantation for people with refractory Crohn’s disease. “There’s been a lot of debate in the community about whether the benefits are worth the risks,” Dr Lindsay pointed out. He said he is looking forward to a fascinating presentation of the largest experience to date with stem cell transplantation in this patient population in Europe.
Results from OPERA II, which is evaluating the long-term efficacy and safety of the anti-MAdCAM monoclonal antibody SHP647 in Crohn’s disease, will also be presented at the meeting.
Identifying Super Donors for Fecal Microbiota Transplant
Some basic science presentations will also be thought-provoking. For example, one of the big questions about fecal microbiota transplantation for patients with ulcerative colitis is “the characteristics of the donor stool that are associated with treatment benefit,” Dr Lindsay said.
Previous research has suggested that stool from certain donors is more effective than stool from other donors. “It may not be just having someone else’s stool; it may be having someone specific’s stool,” he explained. An oral presentation will examine the factors that drive response and remission in patients with ulcerative colitis treated with fecal microbiota transfer. That will be “very interesting,” he added.
The main plenary program is on a single track, “so you don’t have to worry about choosing which presentation to see and then missing something in another hall,” said Dr Lindsay.
“One of the great things about ECCO is that it’s truly multidisciplinary,” he added. The congress is designed to appeal to a wide range of clinicians: physicians, surgeons, nurses, pathologists, dieticians, pharmacists, and basic scientists.
“There is a really nice balance between clinical and translational science, interspersing original data with lectures by an international array of key opinion leaders,” Dr Lindsay said.
The social highlight — ECCO Interaction: Hearts and Minds — will be the Friday evening networking event, Dr Lindsay said. The get-together will be held offsite, in the Wintergarten of the Hofburg Vienna, and tickets must be purchased in advance. The event will offer food, music, and opportunities to meet and network with fellow clinicians and researchers interested in inflammatory bowel disease.
Dr Lindsay is a member of the steering group for the PANTS trial, but receives no financial remuneration.
Follow Medscape Gastroenterology on Twitter @MedscapeGastro and Damian McNamara @MedReporter
Tidak ada komentar:
Posting Komentar